Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image

Here's your US review and approval news in brief for the week: Two more novel drugs have cleared the Food and Drug Administration's review hurdle, with Epizyme Inc.'s Tazverik (tazemetostat) and Horizon Therapeutics PLC's Tepezza (teprotumumab-trbw) becoming the most recent to get the agency's green light.

GlaxoSmithKline PLC is looking to make a splash with its multiple myeloma candidate belantamab mafodotin, which earned a priority...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers